A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:

Inclusion Criteria:

1. Documented symptomatic paroxysmal atrial fibrillation (PAF). Documentationrequirements are as follows:

2. Physician's note indicating recurrent self-terminating AF with ≥ 2 episodes ofPAF within the 6 months prior to enrollment AND

3. One electrocardiographically documented PAF episode within 12 months prior toenrollment. NOTE: Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of continuous AF from another ECG device.

4. Plans to undergo a catheter ablation procedure due to symptomatic PAF and isrefractory, intolerant, or contraindicated to at least one Class I-IV AAD medication

5. At least 18 years of age

6. Able and willing to comply with all trial requirements including pre- procedure,post-procedure, and follow-up testing and requirements

7. Informed of the nature of the trial, agreed to its provisions, and has providedwritten informed consent as approved by the Institutional Review Board/EthicsCommittee (IRB/EC) of the respective clinical trial site.

Exclusion Criteria:

1. Previously diagnosed persistent or long-standing persistent atrial fibrillation (Continuous AF greater than 1 year in duration)

2. Arrhythmia due to reversible causes including thyroid disorders, acute alcoholintoxication, electrolyte imbalance, severe untreated sleep apnea, and other majorsurgical procedures in the preceding 90 days

3. Known presence of cardiac thrombus

4. Left atrial diameter (LAD) > or equal to 5.0 cm (anteroposterior diameter) within 180 days prior to the index procedure

5. Left ventricular ejection fraction (LVEF) < or equal to 35% as assessed withechocardiography or computerized tomography (CT) within 180 days prior to the indexprocedure

6. New York Heart Association (NYHA) class III or IV heart failure

7. Body mass index > or equal to 40 kg/m2

8. Pregnant or nursing

9. Patients who have had a ventriculotomy or atriotomy within the preceding 28 days ofprocedure

10. Myocardial infarction (MI), acute coronary syndrome, percutaneous coronaryintervention (PCI), or valve or coronary bypass grafting surgery within preceding 90days

11. Stroke or TIA (transient ischemic attack) within the last 90 days

12. Heart disease in which corrective surgery is anticipated within 180 days afterprocedure

13. History of blood clotting or bleeding abnormalities including thrombocytosis,thrombocytopenia, bleeding diathesis, or suspected anti- coagulant state

14. Contraindication to long-term anti-thromboembolic therapy

15. Patient unable to receive heparin or an acceptable alternative to achieve adequateanticoagulation

16. Known sensitivity to contrast media (if needed during the procedure) that cannot becontrolled with pre-medication

17. Previous left atrial surgical or left atrial catheter ablation procedure (includingleft atrial appendage (LAA) closure device)

18. Plans to have an LAA closure device implanted during the follow-up period

19. Presence of any condition that precludes appropriate vascular access

20. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2)

21. Previous tricuspid or mitral valve replacement or repair

22. Patients with prosthetic valves

23. Patients with a myxoma

24. Patients with an interatrial baffle or patch as the transseptal puncture couldpersist and produce an iatrogenic atrial shunt

25. Stent, constriction, or stenosis in a pulmonary vein

26. Rheumatic heart disease

27. Hypertrophic cardiomyopathy

28. Active systemic infection

29. Renal failure requiring dialysis

30. Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive orchronic obstructive pulmonary disease) or any other disease or malfunction of thelungs or respiratory system that produces severe chronic symptoms

31. Presence of an implantable therapeutic cardiac device including permanent pacemaker,biventricular pacemaker, or any type of implantable cardiac defibrillator (with orwithout biventricular pacing function) or planned implant of such a device for anytime during the follow-up period. Presence of an implantable loop recorder isacceptable as long as it is removed prior to insertion of the investigationaldevice.

32. Patient is currently participating in another clinical trial or has participated ina clinical trial within 30 days prior to screening that may interfere with thisclinical trial without pre-approval from this study Sponsor

33. Unlikely to survive the protocol follow up period of 12 months

34. Presence of other medical, anatomic, comorbid, social, or psychological conditionsthat, in the investigator's opinion, could limit the subject's ability toparticipate in the clinical investigation or to comply with follow-up requirements,or impact the scientific soundness of the clinical investigation results.

35. Individuals without legal authority

36. Individuals unable to read or write